Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacodynamics of PUL-042 with Cromolyn or Albuterol Pretreatment in Healthy Subjects
NCT02566252Phase 1Completed
- Sponsor
- Pulmotect
- Start
- Jul 2015
- Primary completion
- Jan 2016
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of PUL-042 in respiratory tract infection (RTI) (3 arms), sponsored by Pulmotect. Primary endpoint: Treatment-Emergent Adverse Events at 6 weeks. Started Jul 2015; status: completed.
02
Drugs
PUL-042
03
Conditions
respiratory tract infection (RTI)
Beyond the preview
Go deeper on NCT02566252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02566252.